Singulex | GenomeWeb

Singulex

The automated immunodiagnostics system is based on Singulex's single molecule counting technology.

Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.

The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay. 

The immunoassay firm plans to first develop cardiovascular IVDs on its Clarity instrument, followed by assays in oncology and infectious disease.

Through their arrangement, Singulex has granted Grifols an exclusive license to its single-molecule counting technology for use in blood donor and plasma screening.

Westin St. Francis Hotel, San Francisco, site of the JP Morgan Healthcare Conference

Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.

The deal gives EMD Millipore control of Singulex's single-molecule counting technology for research applications.

The Biomarker Development Center will use Singulex's Single Molecule Counting technology to quantify ultra-low level biomarkers.

The partners will develop biomarkers for potential use in drug development targeting the disease. 

Singulex has appointed Peter Heseltine as chief medical officer.

Pages

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.